MX2021010745A - Metodo para el tratamiento de las mujeres no fumadoras con cancer de pulmon de celulas no peque?as. - Google Patents

Metodo para el tratamiento de las mujeres no fumadoras con cancer de pulmon de celulas no peque?as.

Info

Publication number
MX2021010745A
MX2021010745A MX2021010745A MX2021010745A MX2021010745A MX 2021010745 A MX2021010745 A MX 2021010745A MX 2021010745 A MX2021010745 A MX 2021010745A MX 2021010745 A MX2021010745 A MX 2021010745A MX 2021010745 A MX2021010745 A MX 2021010745A
Authority
MX
Mexico
Prior art keywords
lung cancer
small cell
cell lung
smokers
treating female
Prior art date
Application number
MX2021010745A
Other languages
English (en)
Spanish (es)
Inventor
Aditya Kulkami
Arun Asaithambi
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of MX2021010745A publication Critical patent/MX2021010745A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
MX2021010745A 2019-03-08 2020-03-08 Metodo para el tratamiento de las mujeres no fumadoras con cancer de pulmon de celulas no peque?as. MX2021010745A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815762P 2019-03-08 2019-03-08
PCT/US2020/021615 WO2020185640A1 (en) 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer

Publications (1)

Publication Number Publication Date
MX2021010745A true MX2021010745A (es) 2021-12-15

Family

ID=72427123

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010745A MX2021010745A (es) 2019-03-08 2020-03-08 Metodo para el tratamiento de las mujeres no fumadoras con cancer de pulmon de celulas no peque?as.

Country Status (11)

Country Link
US (1) US20220168258A1 (enExample)
EP (1) EP3935043A4 (enExample)
JP (2) JP2022525040A (enExample)
KR (1) KR20220047208A (enExample)
CN (2) CN113906010A (enExample)
AU (2) AU2020235823A1 (enExample)
BR (1) BR112021017716A2 (enExample)
CA (1) CA3132827A1 (enExample)
MX (1) MX2021010745A (enExample)
SG (1) SG11202109705YA (enExample)
WO (1) WO2020185640A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008352597B2 (en) * 2008-03-14 2012-03-08 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667886B2 (ja) * 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
ES2476602T3 (es) * 2008-03-14 2014-07-15 Bionumerik Pharmaceuticals, Inc. Composiciones y métodos quimioprotectores
US20170007561A1 (en) * 2014-08-08 2017-01-12 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Also Published As

Publication number Publication date
CA3132827A1 (en) 2020-09-17
JP2022525040A (ja) 2022-05-11
US20220168258A1 (en) 2022-06-02
EP3935043A4 (en) 2023-01-11
EP3935043A1 (en) 2022-01-12
KR20220047208A (ko) 2022-04-15
AU2025267367A1 (en) 2025-12-04
BR112021017716A2 (pt) 2021-11-16
WO2020185640A1 (en) 2020-09-17
SG11202109705YA (en) 2021-10-28
CN113906010A (zh) 2022-01-07
AU2020235823A1 (en) 2021-11-04
JP2025081338A (ja) 2025-05-27
CN120078760A (zh) 2025-06-03

Similar Documents

Publication Publication Date Title
BR112022003165A2 (pt) Método de tratamento de cânceres associados a kras
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
ZA202110422B (en) Heterocyclic compounds, preparation methods and uses thereof
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
ZA202006190B (en) Rimegepant for cgrp related disorders
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
WO2019094642A8 (en) T cell manufacturing compositions and methods
EP4417252A3 (en) Cannabis based therapeutic and method of use
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
EP4588484A3 (en) Methods of treating multiple myeloma
EP4696301A3 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
PH12019500957A1 (en) Selective inhibitor of exon 20 insertion mutant egfr
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.
TW201613589A (en) Combination methods for treating cancers
MX2021001516A (es) Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
MX2016011045A (es) Terapia de combinacion para cancer.
EP4578499A3 (en) Resmetirom for reducing liver volume
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
MX2025003936A (es) Combinacion de talazoparib y enzalutamida en el tratamiento del cancer de prostata metastasico resistente a la castracion
WO2020226986A3 (en) Methods of treating cancer with an anti-pd-l1 antibody